INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 135 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2018. The put-call ratio across all filers is 0.27 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $256,273 | +10.6% | 4,918 | +34.4% | 0.00% | – |
| Q2 2023 | $231,688 | +10.5% | 3,659 | -7.5% | 0.00% | – |
| Q4 2022 | $209,734 | -27.7% | 3,954 | -56.5% | 0.00% | – |
| Q4 2020 | $290,000 | -5.2% | 9,088 | -23.9% | 0.00% | -100.0% |
| Q2 2020 | $306,000 | +11.7% | 11,940 | -67.4% | 0.00% | 0.0% |
| Q3 2019 | $274,000 | -73.9% | 36,654 | -24.2% | 0.00% | -50.0% |
| Q3 2018 | $1,049,000 | +414.2% | 48,357 | +318.1% | 0.00% | – |
| Q2 2018 | $204,000 | -89.8% | 11,566 | -87.8% | 0.00% | -100.0% |
| Q1 2018 | $1,996,000 | +1132.1% | 94,808 | +783.1% | 0.00% | – |
| Q4 2016 | $162,000 | – | 10,736 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 640,000 | $25,626,000 | 6.33% |
| Redmile Group, LLC | 1,322,592 | $52,957,000 | 4.01% |
| SENZAR ASSET MANAGEMENT, LLC | 556,224 | $22,271,209,000 | 3.24% |
| RA Capital Management | 314,349 | $12,587,000 | 1.81% |
| WALL STREET ASSOCIATES | 205,657 | $8,235,000 | 1.58% |
| Parametrica Management Ltd | 5,400 | $216,000 | 1.36% |
| Rhenman & Partners Asset Management AB | 165,000 | $6,607,000 | 1.05% |
| EAM Investors, LLC | 95,168 | $3,811,000 | 0.60% |
| Rock Springs Capital Management LP | 180,000 | $7,207,000 | 0.58% |
| WASATCH ADVISORS LP | 1,085,973 | $43,482,000 | 0.58% |